Verici enrols patients for multi-centre study ahead of forecast

The AIM-traded firm said the early completion of enrollment reflected the fact that it remained on track to complete the validation study for the products by the end of 2021, in line with the expectations it set out in its admission document.

It said it had partnered with 11 “leading” United States and European Union centres to-date, to run a global, non-randomised study for the clinical validation of its lead products, ‘Clarava’ and ‘Tuteva’.

The company said the study would use “next-generation” sequencing in the Verici Dx laboratory to create transcriptomic profiles, to validate performance characteristics of the lead Verici Dx signature tests.

Over the longer term, the study would also provide validation for its fibrosis test, called ‘Protega’.

Patient enrolment was continuing for the validation of Protega, and was expected to complete by the third quarter of 2022.

The end points of the validation study for the product were expected to be reached up to two years after the completion of enrolment, with data expected shortly thereafter, around year-end 2024.

“I am delighted to have reached this key milestone ahead of our original expectations,” said chief executive officer Sara Barrington.

“Since initial public offering, our primary focus has been on the successful prosecution of these clinical trials, as the first key step in commercialising our innovative transplant products.

“We remain on track to have our two lead products fully tested by the end of the year and look forward to reporting the data in the first quarter of 2022.”

At 1006 BST, shares in Verici Dx were down 2.04% at 68.08p.